hiv-1 immunogen

Remune (hiv-1 immunogen) is an investigational therapeutic vaccine developed by The Immune Response Corporation for the treatment of HIV-1 infection. It consists of a whole-killed HIV-1 virus (HZ321 isolate) that has been chemically inactivated and depleted of its gp120 envelope glycoprotein, formulated in an oil-based incomplete Freund's adjuvant (IFA). The vaccine is designed to enhance HIV-specific cell-mediated immune responses, particularly T-cell proliferation and Th1 cytokine production, to help control viral replication and slow disease progression. Despite extensive Phase II and Phase III clinical testing, including the large-scale REMUNE trial, the drug failed to demonstrate a significant clinical benefit on primary endpoints such as progression to AIDS or death, leading to the discontinuation of its development in the early 2000s.

Brand names

Remune

Other names

Salk Immunogengp120-depleted HIV-1 immunogengp-120-depleted HIV-1 immunogengp 120-depleted HIV-1 immunogeninactivated HIV-1 immunogenRemune HIV-1 antigen